{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:15:39Z","timestamp":1772590539656,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Development of overt hepatic encephalopathy (oHE) is a particularly feared complication when considering treatment with transjugular intrahepatic portosystemic shunt (TIPS). However, the pathophysiology of HE, in particular after TIPS-insertion, is complex and valid predictors remain scarce. We aimed to investigate whether systemic inflammation markers (SIM) are linked to minimal (mHE) and overt HE (oHE) development before and after TIPS. 62 prospectively recruited patients undergoing TIPS-insertion were included and monitored for oHE occurrence two years thereafter. Patients underwent psychometric testing including the portosystemic encephalopathy syndrome test (PSE), yielding the psychometric hepatic encephalopathy score (PHES), and Animal Naming Test (ANT) before TIPS (baseline) and during structured follow-up 1, 3, 6 and 12 months afterwards. SIM (IL-6, TNF-\u03b1 and IL-1\u03b2) were measured at corresponding timepoints. Patients were predominantly male (64.5%) with a median age of 58 years and MELD of 11. The majority (75.8%) received a TIPS for treatment of refractory ascites. 67.9% presented with mHE before TIPS. No link between the investigated SIM and PHES or ANT at baseline or during any follow-up was documented. 19 (30.6%) patients developed oHE during follow-up. Neither baseline SIM levels nor test results were significantly associated with risk for oHE. We demonstrated a significant decline of all SIM during follow-up, which did not translate to an ameliorated risk for oHE. In patients undergoing TIPS-insertion, the selected SIM have neither a strong link to post-TIPS-oHE development nor to subclinical changes in psychometric tests for mHE.<\/jats:p>","DOI":"10.1007\/s11011-024-01436-2","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T08:51:49Z","timestamp":1733820709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Value of systemic inflammation markers for the detection of minimal and prediction of overt hepatic encephalopathy after TIPS insertion"],"prefix":"10.1007","volume":"40","author":[{"given":"Anja","family":"Tiede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Stockhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena F.","family":"Ehrenbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Rieland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M.","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan B.","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Weissenborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"1436_CR1","doi-asserted-by":"publisher","unstructured":"Agrawal S, Umapathy S, Dhiman RK (2015) Minimal hepatic Encephalopathy impairs Quality of Life. J Clin Experimental Hepatol 5S42\u2013S48. https:\/\/doi.org\/10.1016\/j.jceh.2014.11.006","DOI":"10.1016\/j.jceh.2014.11.006"},{"key":"1436_CR2","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jceh.2014.06.004","volume":"5","author":"DR Aldridge","year":"2015","unstructured":"Aldridge DR, Tranah EJ, Shawcross DL (2015) Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol 5:S7\u2013S20. https:\/\/doi.org\/10.1016\/j.jceh.2014.06.004","journal-title":"J Clin Exp Hepatol"},{"key":"1436_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jgh.13917","volume":"33","author":"J Ampuero","year":"2018","unstructured":"Ampuero J, Montoli\u00fa C, Sim\u00f3n-Talero M, Aguilera V, Mill\u00e1n R, M\u00e1rquez C, Jover R, Rico MC, Sendra C, Serra M\u00c1, Romero-G\u00f3mez M (2018) Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. J Gastroenterol Hepatol 33:718\u2013725. https:\/\/doi.org\/10.1111\/jgh.13917","journal-title":"J Gastroenterol Hepatol"},{"key":"1436_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","volume":"74","author":"V Arroyo","year":"2021","unstructured":"Arroyo V, Angeli P, Moreau R, Jalan R, Cl\u00e0ria J, Trebicka J, Fern\u00e1ndez J, Gustot T, Caraceni P, Bernardi M (2021) The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 74:670\u2013685. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.048","journal-title":"J Hepatol"},{"key":"1436_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/hep.26684","volume":"59","author":"P Berlioux","year":"2014","unstructured":"Berlioux P, Robic MA, Poirson H, M\u00e9tivier S, Otal P, Barret C, Lopez F, P\u00e9ron JM, Vinel JP, Bureau C (2014) Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post\u2010TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology (Baltimore MD) 59:622\u2013629. https:\/\/doi.org\/10.1002\/hep.26684","journal-title":"Hepatology (Baltimore MD)"},{"key":"1436_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.29146","volume":"66","author":"F Campagna","year":"2017","unstructured":"Campagna F, Montagnese S, Ridola L, Senzolo M, Schiff S, De Rui M, Pasquale C, Nardelli S, Pentassuglio I, Merkel C, Angeli P, Riggio O, Amodio P (2017) The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology 66:198\u2013208. https:\/\/doi.org\/10.1002\/hep.29146","journal-title":"Hepatology"},{"key":"1436_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","volume":"74","author":"D Costa","year":"2021","unstructured":"Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, St\u00e4ttermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T (2021) Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol 74:819\u2013828. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.004","journal-title":"J Hepatol"},{"key":"1436_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217\u2013231. https:\/\/doi.org\/10.1016\/j.jhep.2005.10.013","journal-title":"J Hepatol"},{"key":"1436_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","volume":"68","author":"G D\u2019Amico","year":"2018","unstructured":"D\u2019Amico G, Morabito A, D\u2019Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG (2018) Clinical states of cirrhosis and competing risks. J Hepatol 68:563\u2013576. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.020","journal-title":"J Hepatol"},{"key":"1436_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3760\/cma.j.cn501113-20220109-00010","volume":"30","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C (2022) Baveno VII - renewing consensus in portal hypertension: personalized care for portal hypertension. J Hepatol 30:21\u201329. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20220109-00010","journal-title":"J Hepatol"},{"key":"1436_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(95)00148-4","author":"HE de Vires","year":"1996","unstructured":"de Vires HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ, Breimer DD, Kuiper J (1996) The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. https:\/\/doi.org\/10.1016\/0165-5728(95)00148-4","journal-title":"J Neuroimmunol"},{"key":"1436_CR12","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jceh.2014.10.001","volume":"5","author":"N Dharel","year":"2015","unstructured":"Dharel N, Bajaj JS (2015) Definition and nomenclature of hepatic Encephalopathy. J Clin Experimental Hepatol 5:S37\u2013S41. https:\/\/doi.org\/10.1016\/j.jceh.2014.10.001","journal-title":"J Clin Experimental Hepatol"},{"key":"1436_CR13","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.jhepr.2023.100829","volume":"5","author":"AF Ehrenbauer","year":"2023","unstructured":"Ehrenbauer AF, Schneider H, Stockhoff L, Tiede A, Lorenz C, Dirks M, Witt J, Gabriel MM, Wedemeyer H, Hinrichs JB, Weissenborn K, Maasoumy B (2023) Predicting overt hepatic encephalopathy after TIPS: value of three minimal hepatic encephalopathy tests. JHEP Rep 5:100829. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100829","journal-title":"JHEP Rep"},{"key":"1436_CR14","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","volume":"75","author":"C Engelmann","year":"2021","unstructured":"Engelmann C, Cl\u00e0ria J, Szabo G, Bosch J, Bernardi M (2021) Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 75:S49\u2013S66. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.002","journal-title":"J Hepatol"},{"key":"1436_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69:406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol"},{"key":"1436_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","volume":"77","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver (2022) EASL Clinical Practice guidelines on the management of hepatic encephalopathy. J Hepatol 77:807\u2013824. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.001","journal-title":"J Hepatol"},{"key":"1436_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jceh.2018.04.009","volume":"9","author":"CR Flud","year":"2019","unstructured":"Flud CR, Duarte-Rojo A (2019) Prognostic implications of Minimal\/Covert hepatic encephalopathy: large-scale validation cohort studies. J Clin Exp Hepatol 9:112\u2013116. https:\/\/doi.org\/10.1016\/j.jceh.2018.04.009","journal-title":"J Clin Exp Hepatol"},{"key":"1436_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/hep4.1883","volume":"6","author":"SJ Gairing","year":"2022","unstructured":"Gairing SJ, Anders J, Kaps L, Nagel M, Michel M, Kremer WM, Hilscher M, Galle PR, Schattenberg JM, W\u00f6rns M, Labenz C (2022a) Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Commun 6:1113\u20131122. https:\/\/doi.org\/10.1002\/hep4.1883","journal-title":"Hepatol Commun"},{"key":"1436_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/apt.16825","volume":"55","author":"SJ Gairing","year":"2022","unstructured":"Gairing SJ, M\u00fcller L, Kloeckner R, Galle PR, Labenz C (2022b) Review article: post-TIPSS hepatic encephalopathy\u2014current knowledge and future perspectives. Aliment Pharmacol Ther 55:1265\u20131276. https:\/\/doi.org\/10.1111\/apt.16825","journal-title":"Aliment Pharmacol Ther"},{"key":"1436_CR20","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.jhepr.2020.100122","volume":"2","author":"JC Garc\u00eda-Pag\u00e1n","year":"2020","unstructured":"Garc\u00eda-Pag\u00e1n JC, Saffo S, Mandorfer M, Garcia-Tsao G (2020) Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2:100122. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100122","journal-title":"JHEP Rep"},{"key":"1436_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1055\/s-0043-117268","volume":"56","author":"C Labenz","year":"2018","unstructured":"Labenz C, Schattenberg JM (2018) Animal naming test - animals as diagnostic solution? Z Gastroenterol 56:168\u2013169. https:\/\/doi.org\/10.1055\/s-0043-117268","journal-title":"Z Gastroenterol"},{"key":"1436_CR22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/apt.15515","volume":"50","author":"C Labenz","year":"2019","unstructured":"Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, W\u00f6rns M (2019) Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment Pharmacol Ther 50:1112\u20131119. https:\/\/doi.org\/10.1111\/apt.15515","journal-title":"Aliment Pharmacol Ther"},{"key":"1436_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2023.04.028","volume":"79","author":"H Larrue","year":"2023","unstructured":"Larrue H, D\u2019Amico G, Olivas P, Lv Y, Bucsics T, Rudler M, Sauerbruch T, Hernandez-Gea V, Han G, Reiberger T, Thabut D, Vinel J, P\u00e9ron J, Garc\u00eda-Pag\u00e1n J, Bureau C (2023) TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol 79:692\u2013703. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.028","journal-title":"J Hepatol"},{"key":"1436_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/liv.13610","volume":"38","author":"JM Lehmann","year":"2018","unstructured":"Lehmann JM, Claus K, Jansen C, Pohlmann A, Schierwagen R, Meyer C, Thomas D, Manekeller S, Claria J, Strassburg CP, Trautwein C, Wasmuth HE, Berres M, Trebicka J (2018) Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int 38:875\u2013884. https:\/\/doi.org\/10.1111\/liv.13610","journal-title":"Liver Int"},{"key":"1436_CR25","doi-asserted-by":"publisher","unstructured":"Li J, Liu Y, Li M, Rong X, Yuan Z, Ren C, Liu S, Li L, Zhao C, Gao L, Feng D (2023) Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS. Hepatol Commun 7. https:\/\/doi.org\/10.1097\/HC9.0000000000000128","DOI":"10.1097\/HC9.0000000000000128"},{"key":"1436_CR26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00270-014-1035-6","volume":"38","author":"S Marquardt","year":"2015","unstructured":"Marquardt S, Rodt T, Rosenthal H, Wacker F, Meyer BC (2015) Impact of anatomical, procedural, and Operator Skill factors on the success and duration of Fluoroscopy-guided Transjugular Intrahepatic Portosystemic Shunt. Cardiovasc Intervent Radiol 38:903\u2013912. https:\/\/doi.org\/10.1007\/s00270-014-1035-6","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1436_CR27","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1007\/s00261-020-02589-1","volume":"45","author":"TC Meine","year":"2020","unstructured":"Meine TC, Dewald CLA, Becker LS, M\u00e4hringer-Kunz A, Maasoumy B, Maschke SK, Kirstein MM, Werncke T, Wacker FK, Meyer BC, Hinrichs JB (2020) Transjugular intrahepatic portosystemic shunt placement: portal vein puncture guided by 3D\/2D image registration of contrast-enhanced multi-detector computed tomography and fluoroscopy. Abdom Radiol 45:3934\u20133943. https:\/\/doi.org\/10.1007\/s00261-020-02589-1","journal-title":"Abdom Radiol"},{"key":"1436_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/ajg.2016.29","volume":"111","author":"S Nardelli","year":"2016","unstructured":"Nardelli S, Gioia S, Pasquale C, Pentassuglio I, Farcomeni A, Merli M, Salvatori FM, Nikolli L, Torrisi S, Greco F, Nicoletti V, Riggio O (2016) Cognitive impairment predicts the occurrence of hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol 111:523\u2013528. https:\/\/doi.org\/10.1038\/ajg.2016.29","journal-title":"Am J Gastroenterol"},{"key":"1436_CR29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jhep.2023.11.033","volume":"80","author":"S Nardelli","year":"2024","unstructured":"Nardelli S, Riggio O, Marra F, Gioia S, Saltini D, Bellafante D, Adotti V, Guasconi T, Ridola L, Rosi M, Caporali C, Fanelli F, Roccarina D, Bianchini M, Indulti F, Spagnoli A, Merli M, Vizzutti F, Schepis F (2024) Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis. J Hepatol 80:596\u2013602. https:\/\/doi.org\/10.1016\/j.jhep.2023.11.033","journal-title":"J Hepatol"},{"key":"1436_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00270-015-1197-x","volume":"39","author":"K Pereira","year":"2016","unstructured":"Pereira K, Carrion AF, Salsamendi J, Doshi M, Baker R, Kably I (2016) Endovascular management of refractory hepatic Encephalopathy complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm. Cardiovasc Intervent Radiol 39:170\u2013182. https:\/\/doi.org\/10.1007\/s00270-015-1197-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1436_CR31","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jhep.2019.12.021","volume":"72","author":"M Praktiknjo","year":"2020","unstructured":"Praktiknjo M, Sim\u00f3n-Talero M, R\u00f6mer J, Roccarina D, Mart\u00ednez J, Lampichler K, Baiges A, Low G, Llop E, Maurer MH, Zipprich A, Triolo M, Maleux G, Fialla AD, Dam C, Vidal-Gonz\u00e1lez J, Majumdar A, Pic\u00f3n C, Toth D, Darnell A, Abraldes JG, L\u00f3pez M, Jansen C, Chang J, Schierwagen R et al (2020) Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol 72:1140\u20131150. https:\/\/doi.org\/10.1016\/j.jhep.2019.12.021","journal-title":"J Hepatol"},{"key":"1436_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","volume":"58","author":"T Reiberger","year":"2013","unstructured":"Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H (2013) Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58:911\u2013921. https:\/\/doi.org\/10.1016\/j.jhep.2012.12.011","journal-title":"J Hepatol"},{"key":"1436_CR33","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jhep.2020.07.013","volume":"73","author":"CF Rose","year":"2020","unstructured":"Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R (2020) Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 73:1526\u20131547. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.013","journal-title":"J Hepatol"},{"key":"1436_CR34","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/jcm9113784","volume":"9","author":"P Schindler","year":"2020","unstructured":"Schindler P, Heinzow H, Trebicka J, Wildgruber M (2020) Shunt-Induced hepatic encephalopathy in TIPS: current approaches and Clinical challenges. J Clin Med 9:3784. https:\/\/doi.org\/10.3390\/jcm9113784","journal-title":"J Clin Med"},{"key":"1436_CR35","volume-title":"PSE-syndrom-test. Psychodiagnostisches Verfahren Zur Quantitativen Erfassung Der (Minimalen) Portosystemischen Enzephalopathie","author":"H Schomerus","year":"1999","unstructured":"Schomerus H, Weissenborn K, Hamster W, R\u00fcckert N, Hecker H (1999) PSE-syndrom-test. Psychodiagnostisches Verfahren Zur Quantitativen Erfassung Der (Minimalen) Portosystemischen Enzephalopathie. Swets Test Services, Frankfurt"},{"key":"1436_CR36","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11011-019-00490-5","volume":"34","author":"M Senzolo","year":"2019","unstructured":"Senzolo M, Zarantonello L, Formentin C, Orlando C, Beltrame R, Vuerich A, Angeli P, Burra P, Montagnese S (2019) Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. Metab Brain Dis 34:1803\u20131812. https:\/\/doi.org\/10.1007\/s11011-019-00490-5","journal-title":"Metab Brain Dis"},{"key":"1436_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2003.10.016","volume":"40","author":"DL Shawcross","year":"2004","unstructured":"Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40:247\u2013254. https:\/\/doi.org\/10.1016\/j.jhep.2003.10.016","journal-title":"J Hepatol"},{"key":"1436_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11011-006-9042-1","volume":"22","author":"DL Shawcross","year":"2007","unstructured":"Shawcross DL, Wright G, Damink O, S.W.M., and, Jalan R (2007) Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 22:125\u2013138. https:\/\/doi.org\/10.1007\/s11011-006-9042-1","journal-title":"Metab Brain Dis"},{"key":"1436_CR39","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jhep.2010.07.045","volume":"54","author":"DL Shawcross","year":"2011","unstructured":"Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA (2011) Infection and systemic inflammation, not ammonia, are associated with Grade 3\/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 54:640\u2013649. https:\/\/doi.org\/10.1016\/j.jhep.2010.07.045","journal-title":"J Hepatol"},{"key":"1436_CR40","doi-asserted-by":"publisher","unstructured":"Sim\u00f3n-Talero M, Roccarina D, Mart\u00ednez J, Lampichler K, Baiges A, Low G, Llop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsven G, Garcia-Martinez R, Dam A, Majumdar A, Pic\u00f3n C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Ba\u00f1ares R, Laleman W, La Mura V et al (2018) Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology 154:1694\u20131705.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.028","DOI":"10.1053\/j.gastro.2018.01.028"},{"key":"1436_CR41","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/MEG.0000000000001628","volume":"32","author":"CJ Steib","year":"2020","unstructured":"Steib CJ, Li H, Zhang J, Mayerle J, Ricke J, Gerbes AL, Meyer C, Zipprich A, Trebicka J (2020) Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals. Eur J Gastroenterol Hepatol 32:1179\u20131185. https:\/\/doi.org\/10.1097\/MEG.0000000000001628","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1436_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MEG.0b013e328359a759","volume":"25","author":"C Tsien","year":"2013","unstructured":"Tsien C, Shah S, McCullough A, Dasarathy S (2013) Reversal of Sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol 25:85\u201393. https:\/\/doi.org\/10.1097\/MEG.0b013e328359a759","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1436_CR43","doi-asserted-by":"publisher","unstructured":"Weissenborn K (2015) Diagnosis of minimal hepatic encephalopathy. J Clin Experimental Hepatol 5S54\u2013S59. https:\/\/doi.org\/10.1016\/j.jceh.2014.06.005","DOI":"10.1016\/j.jceh.2014.06.005"},{"key":"1436_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40265-018-1018-z","volume":"79","author":"K Weissenborn","year":"2019","unstructured":"Weissenborn K (2019) Hepatic encephalopathy: definition, clinical Grading and Diagnostic principles. Drugs 79:5\u20139. https:\/\/doi.org\/10.1007\/s40265-018-1018-z","journal-title":"Drugs"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-024-01436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-024-01436-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-024-01436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:51:41Z","timestamp":1740549101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-024-01436-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s11011-024-01436-2","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written informed consent to enroll in this prospective study, registered at ClinicalTrials.gov (trial number: NCT04801290). The local ethics committee of Hannover Medical School approved this study (protocol identification number: Nr. 8498_BO_S_2019), which was conducted according to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\u00a0& consent"}},{"value":"Karin Weissenborn: Development of the Psychometric Hepatic Encephalopathy Score (PHES); the copyright of the test is held by Hannover Medical School.Heiner Wedemeyer: Biotest AG (Grants, Consulting), Dr. Falk Pharma (Clinical Trials, Consulting), Norgine (Counsulting, Lectures), Merck KGaA (Consulting, Lectures), Gilead (Clinical Trials, Grants, Consulting, Lectures), Roche (Consulting).Markus Cornberg: AbbVie (Consulting, Lectures), AiCuris (Consulting), Falk (Lectures), Gilead (Consulting, Lectures), GlaxoSmithKline (GSK) (Consulting, Lectures), Janssen (Consulting), Merck\/MSD (Consulting, Lectures), Novartis (Consulting), Roche (Consulting), Swedish Orphan Biovitrum (SOBI) (Consulting).Benjamin Maasoumy: MSD (Lectures), Falk (Lectures), AbbVie (Lectures, Consulting), Astellas (Lectures), Medical Tribune (Lectures), Norgine (Lectures, Consulting), Fujirebio (Lectures, Research Grants), Roche (Lectures, Consulting, Research Grants), Gilead (Lectures), Gore (Lectures), Luvos (Consulting), Altona Diagnostics (Research Grants).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"58"}}